161 related articles for article (PubMed ID: 23353592)
1. Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro.
Weiss J; Theile D; Rüppell MA; Speck T; Spalwisz A; Haefeli WE
Eur J Pharmacol; 2013 Feb; 701(1-3):168-75. PubMed ID: 23353592
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes.
Lepist EI; Gillies H; Smith W; Hao J; Hubert C; St Claire RL; Brouwer KR; Ray AS
PLoS One; 2014; 9(1):e87548. PubMed ID: 24498134
[TBL] [Abstract][Full Text] [Related]
3. Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro.
Weiss J; Haefeli WE
Int J Antimicrob Agents; 2013 May; 41(5):484-7. PubMed ID: 23428312
[TBL] [Abstract][Full Text] [Related]
4. Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro.
Weiss J; Haefeli WE
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1093-8. PubMed ID: 21805352
[TBL] [Abstract][Full Text] [Related]
5. Desmethyl bosentan displays a similar in vitro interaction profile as bosentan.
Weiss J; Baumann S; Theile D; Haefeli WE
Pulm Pharmacol Ther; 2015 Feb; 30():80-6. PubMed ID: 25535031
[TBL] [Abstract][Full Text] [Related]
6. Telaprevir is a substrate and moderate inhibitor of P-glycoprotein, a strong inductor of ABCG2, but not an activator of PXR in vitro.
Weiss J; Becker JP; Haefeli WE
Int J Antimicrob Agents; 2014 Feb; 43(2):184-8. PubMed ID: 24332840
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic interaction profile of riociguat, a new soluble guanylate cyclase stimulator, in vitro.
Rickert V; Haefeli WE; Weiss J
Pulm Pharmacol Ther; 2014 Aug; 28(2):130-7. PubMed ID: 24657506
[TBL] [Abstract][Full Text] [Related]
8. The endothelin receptor antagonist macitentan for the treatment of pulmonary arterial hypertension: A cross-species comparison of its cytochrome P450 induction pattern.
Treiber A; Delahaye S; Seeland S; Gnerre C
Pharmacol Res Perspect; 2020 Aug; 8(4):e00619. PubMed ID: 32613761
[TBL] [Abstract][Full Text] [Related]
9. Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro.
Weiss J; Herzog M; Haefeli WE
Eur J Pharmacol; 2011 Jun; 660(2-3):298-304. PubMed ID: 21501604
[TBL] [Abstract][Full Text] [Related]
10. Macitentan does not interfere with hepatic bile salt transport.
Treiber A; Äänismaa P; de Kanter R; Delahaye S; Treher M; Hess P; Sidharta P
J Pharmacol Exp Ther; 2014 Jul; 350(1):130-43. PubMed ID: 24769543
[TBL] [Abstract][Full Text] [Related]
11. Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells.
Weiss J; Theile D; Spalwisz A; Burhenne J; Riedel KD; Haefeli WE
Biochem Pharmacol; 2013 Jan; 85(2):265-73. PubMed ID: 23219525
[TBL] [Abstract][Full Text] [Related]
12. Distinct ETA receptor binding mode of macitentan as determined by site directed mutagenesis.
Gatfield J; Mueller Grandjean C; Bur D; Bolli MH; Nayler O
PLoS One; 2014; 9(9):e107809. PubMed ID: 25226600
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of the enantiomers of tamsulosin and tolterodine on P-glycoprotein and cytochrome P450 3A4.
Doricakova A; Theile D; Weiss J; Vrzal R
Naunyn Schmiedebergs Arch Pharmacol; 2017 Jan; 390(1):49-59. PubMed ID: 27678410
[TBL] [Abstract][Full Text] [Related]
14. Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension.
Iglarz M; Bossu A; Wanner D; Bortolamiol C; Rey M; Hess P; Clozel M
Life Sci; 2014 Nov; 118(2):333-9. PubMed ID: 24582812
[TBL] [Abstract][Full Text] [Related]
15. Functional estimation of endothelin-1 receptor antagonism by bosentan, macitentan and ambrisentan in human pulmonary and radial arteries in vitro.
Angus JA; Soeding PF; Hughes RJA; Wright CE
Eur J Pharmacol; 2017 Jun; 804():111-116. PubMed ID: 28300593
[TBL] [Abstract][Full Text] [Related]
16. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes.
Hartman JC; Brouwer K; Mandagere A; Melvin L; Gorczynski R
Can J Physiol Pharmacol; 2010 Jun; 88(6):682-91. PubMed ID: 20628435
[TBL] [Abstract][Full Text] [Related]
18. Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects.
Atsmon J; Dingemanse J; Shaikevich D; Volokhov I; Sidharta PN
Clin Pharmacokinet; 2013 Aug; 52(8):685-92. PubMed ID: 23568224
[TBL] [Abstract][Full Text] [Related]
19. Interaction potential of the multitargeted receptor tyrosine kinase inhibitor dovitinib with drug transporters and drug metabolising enzymes assessed in vitro.
Weiss J; Theile D; Dvorak Z; Haefeli WE
Pharmaceutics; 2014 Dec; 6(4):632-50. PubMed ID: 25521244
[TBL] [Abstract][Full Text] [Related]
20. Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects.
Csonka D; Bruderer S; Schultz A; Soergel M; Stepanova R; Sabattini G; Perez-Ruixo JJ
Clin Drug Investig; 2019 Dec; 39(12):1223-1232. PubMed ID: 31552642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
